Insider · CIK 0001801917

Venker Eric

Reports to the SEC for 4 companies · LONDON

sec.gov

Transactions

Companies

Filings

CIK

0001801917

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-20	ROIVRoivant Sciences Ltd.S Sale	President & Immunovant CEO	SSale	−14.1K sh	$35.42	−$501K	1,399,154
2026-10-20	ROIVRoivant Sciences Ltd.S Sale	President & Immunovant CEO	SSale	−186K sh	$35.09	−$6.52M	1,413,298
2026-10-02	IMVTImmunovant, Inc.S Sale	Director, Chief Executive Officer	SSale	−3,506 sh	$34.11	−$120K	257,075
2026-10-01	IMVTImmunovant, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+92.2K sh	$14.46	+$1.33M	346,467
2026-10-01	IMVTImmunovant, Inc.D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−85.9K sh	$33.65	−$2.89M	260,581
2026-10-01	IMVTImmunovant, Inc. · Capped Value Appreciation RightsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−92.2K sh	—	—	921,875
2026-09-30	ROIVRoivant Sciences Ltd.M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	+200K sh	$3.85	+$770K	1,799,154
2026-09-30	ROIVRoivant Sciences Ltd.S Sale	President & Immunovant CEO	SSale	−200K sh	$36.62	−$7.32M	1,599,154
2026-09-30	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	−200K sh	—	—	3,644,834
2026-08-28	ROIVRoivant Sciences Ltd.M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	+200K sh	$3.85	+$770K	1,799,154
2026-08-28	ROIVRoivant Sciences Ltd.S Sale	President & Immunovant CEO	SSale	−166K sh	$35.63	−$5.92M	1,632,972
2026-08-28	ROIVRoivant Sciences Ltd.S Sale	President & Immunovant CEO	SSale	−33.8K sh	$36.44	−$1.23M	1,599,154
2026-08-28	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	−200K sh	—	—	3,844,834
2026-08-20	ROIVRoivant Sciences Ltd.F Tax Payment	President & Immunovant CEO	FTax Payment	−13.9K sh	$36.84	−$512K	1,599,154
2026-07-27	ROIVRoivant Sciences Ltd.M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	+200K sh	$3.85	+$770K	1,813,063
2026-07-27	ROIVRoivant Sciences Ltd.S Sale	President & Immunovant CEO	SSale	−200K sh	$34.95	−$6.99M	1,613,063
2026-07-27	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	−200K sh	—	—	4,044,834
2026-07-02	IMVTImmunovant, Inc.S Sale	Director, Chief Executive Officer	SSale	−3,092 sh	$38.48	−$119K	254,280
2026-07-01	IMVTImmunovant, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+92.2K sh	$14.46	+$1.33M	344,001
2026-07-01	IMVTImmunovant, Inc.D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−86.6K sh	$38.14	−$3.3M	257,372
2026-07-01	IMVTImmunovant, Inc. · Capped Value Appreciation RightsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−92.2K sh	—	—	1,014,062
2026-06-24	ROIVRoivant Sciences Ltd.M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	+200K sh	$3.85	+$770K	1,813,063
2026-06-24	ROIVRoivant Sciences Ltd.S Sale	President & Immunovant CEO	SSale	−154K sh	$33.05	−$5.08M	1,659,297
2026-06-24	ROIVRoivant Sciences Ltd.S Sale	President & Immunovant CEO	SSale	−46.2K sh	$33.51	−$1.55M	1,613,063
2026-06-24	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	−200K sh	—	—	4,244,834
2026-05-22	ROIVRoivant Sciences Ltd.M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	+200K sh	$3.85	+$770K	1,813,063
2026-05-22	ROIVRoivant Sciences Ltd.S Sale	President & Immunovant CEO	SSale	−200K sh	$30.27	−$6.05M	1,613,063
2026-05-22	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	−200K sh	—	—	4,444,834
2026-05-20	ROIVRoivant Sciences Ltd.F Tax Payment	President & Immunovant CEO	FTax Payment	−34.5K sh	$32.41	−$1.12M	1,613,063
2026-04-20	ROIVRoivant Sciences Ltd.M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	+200K sh	$3.85	+$770K	1,847,546
2026-04-20	ROIVRoivant Sciences Ltd.S Sale	President & Immunovant CEO	SSale	−200K sh	$29.59	−$5.92M	1,647,546
2026-04-20	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	−200K sh	—	—	4,644,834
2026-04-07	IMVTImmunovant, Inc.A Award	Director, Chief Executive Officer	AAward	+232K sh	—	—	251,813
2026-04-07	IMVTImmunovant, Inc. · Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+336K sh	—	—	336,043
2026-04-02	IMVTImmunovant, Inc.S Sale	Director, Chief Executive Officer	SSale	−12.8K sh	$24.04	−$308K	20,970
2026-04-02	IMVTImmunovant, Inc.S Sale	Director, Chief Executive Officer	SSale	−1,409 sh	$24.60	−$34.7K	19,561
2026-04-01	IMVTImmunovant, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+369K sh	$14.46	+$5.33M	368,750
2026-04-01	IMVTImmunovant, Inc.D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−335K sh	$25.10	−$8.41M	33,790
2026-04-01	IMVTImmunovant, Inc. · Capped Value Appreciation RightsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−369K sh	—	—	1,106,250
2026-03-17	ROIVRoivant Sciences Ltd.M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	+200K sh	$3.85	+$770K	1,847,546
2026-03-17	ROIVRoivant Sciences Ltd.S Sale	President & Immunovant CEO	SSale	−200K sh	$28.24	−$5.65M	1,647,546
2026-03-17	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	−200K sh	—	—	4,844,834
2026-02-20	ROIVRoivant Sciences Ltd.F Tax Payment	President & Immunovant CEO	FTax Payment	−7,051 sh	$27.15	−$191K	1,647,546
2026-02-13	ROIVRoivant Sciences Ltd.M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	+200K sh	$3.85	+$770K	1,854,597
2026-02-13	ROIVRoivant Sciences Ltd.S Sale	President & Immunovant CEO	SSale	−200K sh	$26.49	−$5.3M	1,654,597
2026-02-13	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	−200K sh	—	—	5,044,834
2026-01-12	ROIVRoivant Sciences Ltd.M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	+200K sh	$3.85	+$770K	1,854,597
2026-01-12	ROIVRoivant Sciences Ltd.S Sale	President & Immunovant CEO	SSale	−200K sh	$21.92	−$4.38M	1,654,597
2026-01-12	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	−200K sh	—	—	5,244,834
2025-12-24	ROIVRoivant Sciences Ltd.M Exercise/Conversion	President & Immunovant CEO	MExercise/Conversion	+118K sh	$3.85	+$454K	1,729,597

Recent filings

Accepted (ET)
Oct 224
Venker Eric0001635088-26-000116
SEC(opens sec.gov)
Oct 54
Venker Eric0001764013-26-000110
SEC(opens sec.gov)
Oct 24
Venker Eric0001635088-26-000108
SEC(opens sec.gov)
Sep 14
Venker Eric0001140361-26-035375
SEC(opens sec.gov)
Aug 244
Venker Eric0001140361-26-034238
SEC(opens sec.gov)
Jul 294
Venker Eric0001140361-26-030107
SEC(opens sec.gov)
Jul 64
Venker Eric0001764013-26-000077
SEC(opens sec.gov)

Companies

Address

C/O ROIVANT SCIENCES LTD. 7TH FLOOR, 50 BROADWAY

LONDON, SW1H 0DB